Oryzon Genomics S.A. (0RDB.L)
EUR 2.68
(2.88%)
EUR 2.68
(2.88%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 6.93 Million USD | -36.96% |
| 2022 | 10.99 Million USD | -27.67% |
| 2021 | 15.19 Million USD | 43.33% |
| 2020 | 10.6 Million USD | 41.12% |
| 2019 | 7.51 Million USD | -34.26% |
| 2018 | 11.43 Million USD | -40.61% |
| 2017 | 19.24 Million USD | 3.17% |
| 2016 | 18.65 Million USD | 178.07% |
| 2015 | 6.7 Million USD | -13.67% |
| 2014 | 7.77 Million USD | -38.1% |
| 2013 | 12.55 Million USD | 57.67% |
| 2012 | 7.96 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 7.27 Million USD | 0.0% |
| 2023 Q2 | 9.27 Million USD | 0.0% |
| 2023 Q4 | 6.93 Million USD | 0.0% |
| 2022 Q2 | 11.93 Million USD | 0.0% |
| 2022 Q4 | 11.07 Million USD | 0.0% |
| 2022 FY | 11.07 Million USD | -27.11% |
| 2021 Q4 | 15.19 Million USD | 0.0% |
| 2021 Q2 | 14.48 Million USD | 0.0% |
| 2021 Q3 | - USD | -100.0% |
| 2021 FY | 15.19 Million USD | 43.33% |
| 2020 Q4 | 10.6 Million USD | -3.59% |
| 2020 FY | 10.6 Million USD | 41.12% |
| 2020 Q1 | 5.72 Million USD | -23.77% |
| 2020 Q2 | 10.79 Million USD | 88.39% |
| 2020 Q3 | 10.99 Million USD | 1.92% |
| 2019 Q2 | 7.74 Million USD | -14.4% |
| 2019 Q1 | 9.04 Million USD | -20.84% |
| 2019 FY | 7.51 Million USD | -34.26% |
| 2019 Q4 | 7.51 Million USD | 11.68% |
| 2019 Q3 | 6.72 Million USD | -13.13% |
| 2018 Q2 | 14.2 Million USD | -16.91% |
| 2018 Q1 | 17.09 Million USD | -11.16% |
| 2018 FY | 11.43 Million USD | -40.61% |
| 2018 Q4 | 11.43 Million USD | -6.19% |
| 2018 Q3 | 12.18 Million USD | -14.23% |
| 2017 Q3 | 15.84 Million USD | -6.16% |
| 2017 Q1 | 17.39 Million USD | -6.73% |
| 2017 FY | 19.24 Million USD | 3.17% |
| 2017 Q4 | 19.24 Million USD | 21.47% |
| 2017 Q2 | 16.88 Million USD | -2.95% |
| 2016 Q2 | 20.96 Million USD | 22.2% |
| 2016 FY | 18.65 Million USD | 178.07% |
| 2016 Q4 | 18.65 Million USD | -13.05% |
| 2016 Q3 | 21.45 Million USD | 2.31% |
| 2016 Q1 | 17.15 Million USD | 155.78% |
| 2015 Q1 | - USD | -100.0% |
| 2015 FY | 6.7 Million USD | -13.67% |
| 2015 Q4 | 6.7 Million USD | 0.0% |
| 2015 Q2 | 7.7 Million USD | 0.0% |
| 2014 Q3 | 8.1 Million USD | 0.0% |
| 2014 Q4 | 7.77 Million USD | -4.09% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 7.77 Million USD | -38.1% |
| 2013 FY | 12.55 Million USD | 57.67% |
| 2012 FY | 7.96 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Boiron SA | 6.64 Million EUR | -4.294% |
| Laboratorios Farmaceuticos Rovi, S.A. | 38.57 Million EUR | 82.034% |
| Vetoquinol SA | 9.66 Million EUR | 28.28% |
| Valneva SE | 132.76 Million EUR | 94.78% |
| AB Science S.A. | 16.98 Million EUR | 59.204% |
| Nanobiotix S.A. | 41.66 Million EUR | 83.365% |
| PHAXIAM Therapeutics S.A. | 7.03 Million EUR | 1.418% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |
| BioSenic S.A. | 15.57 Million EUR | 55.498% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 84.495% |
| Formycon AG | 7.81 Million EUR | 11.32% |